Response to Comments: MolDX: Molecular Testing for Risk Stratification of Thyroid Nodules

This document (A59748) is a response to comments on the MolDX LCD DL39684 (molecular testing for thyroid nodules) and does not itself establish coverage criteria, limitations, documentation requirements, or frequency limits. For definitive coverage rules and claim documentation, consult the final MolDX LCD DL39684, which becomes effective 2024-10-13.

"This response-to-comments document does not itself define clinical coverage indications; consult MolDX Local Coverage Determination DL39684 for authorized indications for molecular testing of thyro..."

Sign up to see full coverage criteria, indications, and limitations.